UroGen Pharma (URGN) Common Equity (2016 - 2026)

UroGen Pharma (URGN) has 11 years of Common Equity data on file, last reported at -$124.3 million in Q1 2026.

• Quarterly Common Equity fell 167.45% year-over-year to -$124.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$124.3 million (down 167.45% YoY) and the FY2025 annual result came in at -$105.5 million, down 1098.16% from the prior year.
• Common Equity retreated to -$124.3 million in Q1 2026, from -$105.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $30.3 million in Q2 2024 to a low of -$138.4 million in Q2 2023.
• A 5-year average of -$61.8 million and a median of -$63.3 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity slumped 1162.18% — and 2024, when it jumped 160.76%.
• Tracing URGN's Common Equity over 5 years: stood at -$89.4 million in 2022, then gained by 27.02% to -$65.2 million in 2023, then surged by 86.5% to -$8.8 million in 2024, then tumbled by 1098.16% to -$105.5 million in 2025, then slipped by 17.8% to -$124.3 million in 2026.
• The last three Common Equity figures came in at -$124.3 million (Q1 2026), -$105.5 million (Q4 2025), and -$115.4 million (Q3 2025), per Business Quant data.